Genscript Biotech Corporation (G51) - Total Assets
Based on the latest financial reports, Genscript Biotech Corporation (G51) holds total assets worth €4.85 Billion EUR (≈ $5.67 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genscript Biotech Corporation - Total Assets Trend (2016–2025)
This chart illustrates how Genscript Biotech Corporation's total assets have evolved over time, based on quarterly financial data. Also see Genscript Biotech Corporation (G51) total market value for the company's overall valuation and market capitalisation.
Genscript Biotech Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
Genscript Biotech Corporation's total assets of €4.85 Billion consist of 22.2% current assets and 77.8% non-current assets. Review how much debt does Genscript Biotech Corporation carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.9% |
| Accounts Receivable | €130.22 Million | 2.7% |
| Inventory | €39.59 Million | 0.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €13.25 Million | 0.3% |
| Goodwill | €1.37 Million | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Genscript Biotech Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Genscript Biotech Corporation (G51) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genscript Biotech Corporation's current assets represent 22.2% of total assets in 2025, a decrease from 72.5% in 2016.
- Cash Position: Cash and equivalents constituted 2.9% of total assets in 2025, down from 60.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 2.7% of total assets.
Genscript Biotech Corporation Competitors by Total Assets
Key competitors of Genscript Biotech Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Genscript Biotech Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.50 | 1.07 | 3.03 |
| Quick Ratio | 1.44 | 1.03 | 2.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €358.80 Million | €53.90 Million | €665.26 Million |
Genscript Biotech Corporation - Advanced Valuation Insights
This section examines the relationship between Genscript Biotech Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.06 |
| Latest Market Cap to Assets Ratio | 0.69 |
| Asset Growth Rate (YoY) | -8.1% |
| Total Assets | €4.85 Billion |
| Market Capitalization | $3.36 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Genscript Biotech Corporation's assets below their book value (0.69x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genscript Biotech Corporation's assets decreased by 8.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genscript Biotech Corporation (2016–2025)
The table below shows the annual total assets of Genscript Biotech Corporation from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €4.85 Billion ≈ $5.67 Billion |
-8.05% |
| 2024-12-31 | €5.28 Billion ≈ $6.17 Billion |
+55.83% |
| 2023-12-31 | €3.39 Billion ≈ $3.96 Billion |
+33.02% |
| 2022-12-31 | €2.55 Billion ≈ $2.98 Billion |
+14.05% |
| 2021-12-31 | €2.23 Billion ≈ $2.61 Billion |
+54.26% |
| 2020-12-31 | €1.45 Billion ≈ $1.69 Billion |
+62.74% |
| 2019-12-31 | €889.41 Million ≈ $1.04 Billion |
-3.01% |
| 2018-12-31 | €916.98 Million ≈ $1.07 Billion |
+81.84% |
| 2017-12-31 | €504.26 Million ≈ $589.54 Million |
+123.09% |
| 2016-12-31 | €226.03 Million ≈ $264.26 Million |
-- |
About Genscript Biotech Corporation
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Scien… Read more